YOLA SARA: Open Payments
NPI 1649842923 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,081 in 140 payments from 16 companies in 2025. Trend: 2023 $1,351 · 2024 $2,383 · 2025 $4,081
Food & beverage: $4,081
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 21 | $857 |
| ABBVIE INC. | 34 | $839 |
| Novo Nordisk Inc | 18 | $482 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $453 |
| GlaxoSmithKline, LLC. | 13 | $346 |
| Lilly USA, LLC | 11 | $339 |
| Otsuka America Pharmaceutical, Inc. | 11 | $280 |
| Xeris Pharmaceuticals, Inc. | 5 | $208 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $86 |
| SANOFI-AVENTIS U.S. LLC | 3 | $59 |
Products named: VRAYLAR, CAPLYTA, AIRSUPRA, REXULTI, FARXIGA, Wegovy, TRELEGY ELLIPTA, FASENRA.
Industry payments across PA — which companies pay providers there.
